• Keine Ergebnisse gefunden

Correction to: Diagnostic performance of four SARS‑CoV‑2 antibody assays in patients with COVID‑19 or with bacterial and non‑SARS‑CoV‑2 viral respiratory infections

N/A
N/A
Protected

Academic year: 2022

Aktie "Correction to: Diagnostic performance of four SARS‑CoV‑2 antibody assays in patients with COVID‑19 or with bacterial and non‑SARS‑CoV‑2 viral respiratory infections"

Copied!
6
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Vol.:(0123456789)

1 3

https://doi.org/10.1007/s10096-021-04301-7 CORRECTION

Correction to: Diagnostic performance of four SARS‑CoV‑2 antibody assays in patients with COVID‑19 or with bacterial and non‑SARS‑CoV‑2 viral respiratory infections

Timo Huber

1

 · Philipp Steininger

2

 · Pascal Irrgang

2

 · Klaus Korn

2

 · Matthias Tenbusch

2

 · Katharina Diesch

3

 · Susanne Achenbach

4

 · Andreas E. Kremer

5

 · Marissa Werblow

1

 · Marcel Vetter

5

 · Christian Bogdan

1,6

 · Jürgen Held

1

© Springer-Verlag GmbH Germany, part of Springer Nature 2021

Correction to: European Journal of Clinical Microbiology & Infectious Diseases https://doi.org/10.1007/s10096-021-04285-4

The original article can be found online at https:// doi. org/ 10. 1007/

s10096- 021- 04285-4.

* Jürgen Held

juergen.held@uk-erlangen.de

1 Mikrobiologisches Institut—Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen- Nürnberg, Wasserturmstr. 3/5, 91054 Erlangen, Germany

2 Virologisches Institut—Klinische und Molekulare Virologie, Universitätsklinikum Erlangen und

Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany

3 Center for Medical Information and Communication Technology, Universitätsklinikum Erlangen, Erlangen, Germany

4 Transfusionsmedizinische und Hämostaseologische Abteilung, Universitätsklinikum Erlangen und

Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Krankenhausstraße 12, 91054 Erlangen, Germany

5 Department of Medicine 1, University Hospital Erlangen and Deutsches Zentrum Immuntherapie DZI, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Ulmenweg 18, 91054 Erlangen, Germany

6 Medical Immunology Campus Erlangen, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Schlossplatz 1, 91054 Erlangen, Germany

In the originally published version of the article, captions of Figures 1, 2, 3, 4, and 5 have missing figure denominations.

The figures are presented here with correct captions.

Layout adjustments are also made to Tables 2-5 for readability.

The original article has been corrected.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published online: 16 July 2021

European Journal of Clinical Microbiology & Infectious Diseases (2021) 40:1999–2004

(2)

1 3

Fig. 1 Categorical results of antibody indices against time after the onset of symptoms from the COVID-19 group. Black bars, light gray bars, or dark gray bars indicate a negative, equivocal, or positive test

result, respectively. a) Vircell-IgM/A b) Euroimmun-IgA c) Vircell- IgG d) Euroimmun-IgG

2000 European Journal of Clinical Microbiology & Infectious Diseases (2021) 40:1999–2004

(3)

1 3

Fig. 2 Box-plots of anti-SARS-CoV-2 antibody indices against time after the onset of symptoms from the COVID-19 group. The red dot- ted line indicates the lower manufacturer’s cutoff value (equivocal

results are rated as positive results). Circles and stars depict outliers and extreme outliers, respectively. a) Vircell-IgM/A b) Euroimmun- IgA c) Vircell-IgG d) Euroimmun-IgG

2001 European Journal of Clinical Microbiology & Infectious Diseases (2021) 40:1999–2004

(4)

1 3

Fig. 3 Box-plots of anti-SARS-CoV-2 antibody indices against dis- ease severity from the COVID-19 group. The red dotted line indicates the lower manufacturer’s cutoff value (equivocal results are rated as

positive results). Circles and stars depict outliers and extreme outli- ers, respectively. a) Vircell-IgM/A b) Euroimmun-IgA c) Vircell-IgG d) Euroimmun-IgG

2002 European Journal of Clinical Microbiology & Infectious Diseases (2021) 40:1999–2004

(5)

1 3

Fig. 4 Box-plots of anti-SARS-CoV-2 antibody indices from the bacterial infection group and the control group. The red dotted line indicates the lower manufacturer’s cutoff value (equivocal results are

rated positive results). Circles and stars depict outliers and extreme outliers, respectively. a) Vircell-IgM/A b) Euroimmun-IgA c) Vir- cell-IgG d) Euroimmun-IgG

2003 European Journal of Clinical Microbiology & Infectious Diseases (2021) 40:1999–2004

(6)

1 3

Fig. 5 Box-plots of anti-SARS-CoV-2 antibody indices from the viral infection group and the control group. The red dotted line indicates the lower manufacturer’s cutoff value (equivocal results are rated

positive results). Circles and stars depict outliers and extreme outli- ers, respectively. a) Vircell-IgM/A b) Euroimmun-IgA c) Vircell-IgG d) Euroimmun-IgG

2004 European Journal of Clinical Microbiology & Infectious Diseases (2021) 40:1999–2004

Referenzen

ÄHNLICHE DOKUMENTE

With regard to the two-step procedure that uses independent reverse transcription and subsequent ddPCR, among the six RT kits used, the iScript™ Advanced cDNA Synthesis Kit

5: Laboratoire de Biologie Médicale, Groupe Hospitalier Nord-Essonne, Site de Longjumeau, Longjumeau, France.. 6 : Laboratoire de Biologie Médicale, Groupe

Here, we compared four enzyme-linked immunosorbent assays (ELISAs; Vircell SARS-CoV-2 IgM/IgA and IgG, Euroimmun SARS-CoV-2 IgA and IgG) for detection of anti-SARS-CoV-2 antibodies

Timo Huber, Philipp Steininger, Pascal Irrgang, Klaus Korn, Matthias Tenbusch, Katharina Diesch, Susanne Achenbach, Andreas E.. Kremer, Marissa Werblow, Marcel Vetter, Christian

Conclusion: The Elecsys Anti-SARS-CoV-2 immunoassay demonstrated very high specificity and high sensitivity in samples collected at least 14 days post-PCR confirmation of

** Results in 46 patients with treatment delay due to SARS-CoV-2 infection; 80% had stable and 20% progressive disease; *** Illustration of subsequent cancer treatment in 45

By including a large number of university and cantonal hospitals, we collected 3650 cases confirmed by PCR as of 1 September 2020 and 527 (14.7%) COVID-19 related deaths.. On the

Here, we employed the human airway epithelial cell (hAEC) culture model to investigate the influence of different incubation temperatures on the viral replication kinetics and